Sign in Subscribe
Cybernet Data Systems Inc.

Daxor Corporation Receives National Institutes of Health (NIH) Funding for Landmark Heart Failure Trial

Strategic Insights

— 2 min read

Daxor Corporation, the global leader in blood volume measurement technology, has announced the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume Analysis-guided management of acute decompensated heart failure (ADHF) utilizing the BVA-100 blood test. This trial aims to determine the benefit of goal-directed care guided by Daxor's blood volume measurement system, resulting in more appropriate treatment and consistent achievement of optimal blood volume. The study's primary objective is to determine the benefit of BVA-100 guided care in addition to usual care, leading to improved patient outcomes.

The trial will involve over 6 million Americans suffering from heart failure, which is one of the most prevalent and deadly diseases, resulting in nearly 1 million deaths and 1 million hospitalizations annually. The study's principal investigator, Dr. Jacob Joseph, Director of Heart Failure Program at VA Boston Healthcare System, will lead the investigation. The trial is expected to provide high-quality clinical data driving the adoption of Daxor's unique technology broadly, as well as validation of Daxor's patent-pending clinical guidance system.

Key Takeaways:

  • **Significant clinical trial milestone**: Daxor Corporation has initiated a landmark multi-center heart failure trial using the BVA-100 blood test with the United States Department of Veterans Affairs.
  • **Worldwide reach**: The trial aims to involve over 6 million Americans suffering from heart failure, one of the most prevalent and deadly diseases.
  • **Improved outcomes**: The study's primary objective is to determine the benefit of BVA-100 guided care in addition to usual care, leading to improved patient outcomes.
  • **Patent-pending technology**: Daxor's patent-pending clinical guidance system is expected to be validated through this study, driving the adoption of this unique technology broadly.
  • **Funding and initiative**: The trial was initiated with the National Institutes of Health (NIH) funding notification, converging with Daxor's planned next-generation analyzer product development schedule.
  • **Next-generation system**: Daxor is developing a next-generation analyzer system, which promises to be faster, easier, and expand the use of the test into more clinical settings for more indications.

Statistics:

  • **6 million Americans affected by heart failure**: Over 6 million Americans are living with heart failure, making it a serious public health concern.
  • **1 million deaths and 1 million hospitalizations annually**: Heart failure results in nearly 1 million deaths and 1 million hospitalizations annually.
  • **Reduced mortality rates**: Past published data has shown BVA-100 guided care has led to reductions in patient mortality of over 82% and 56% for readmissions.
  • **Study identifier**: The trial's identifier is NCT04855097, and it is listed on ClinicalTrials.gov.

Sources:

  • Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100 (Blood Volume Analyzer) with the United States Department of Veterans Affairs (Source: Daxor Corporation press release dated May 6, 2021).
  • ClinicalTrials.gov (Source: Identifier: NCT04855097).

Read more